99 related articles for article (PubMed ID: 12736115)
1. Loss of hMLH1 expression correlates with improved survival in stage III-IV ovarian cancer patients.
Scartozzi M; De Nictolis M; Galizia E; Carassai P; Bianchi F; Berardi R; Gesuita R; Piga A; Cellerino R; Porfiri E
Eur J Cancer; 2003 May; 39(8):1144-9. PubMed ID: 12736115
[TBL] [Abstract][Full Text] [Related]
2. Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy.
Samimi G; Fink D; Varki NM; Husain A; Hoskins WJ; Alberts DS; Howell SB
Clin Cancer Res; 2000 Apr; 6(4):1415-21. PubMed ID: 10778972
[TBL] [Abstract][Full Text] [Related]
3. Analysis of hMLH1 and hMSH2 expression in cisplatin-treated ovarian cancer patients.
Magnowska M; Surowiak P; Nowak-Markwitz E; Michalak M; Magnowski P; Rokita W; Kedzia H; Zabel M; Spaczyński M
Ginekol Pol; 2008 Dec; 79(12):826-34. PubMed ID: 19175039
[TBL] [Abstract][Full Text] [Related]
4. hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents.
Brown R; Hirst GL; Gallagher WM; McIlwrath AJ; Margison GP; van der Zee AG; Anthoney DA
Oncogene; 1997 Jul; 15(1):45-52. PubMed ID: 9233776
[TBL] [Abstract][Full Text] [Related]
5. Mismatch repair system (MMR) status correlates with response and survival in non-small cell lung cancer (NSCLC) patients.
Scartozzi M; Franciosi V; Campanini N; Benedetti G; Barbieri F; Rossi G; Berardi R; Camisa R; Silva RR; Santinelli A; Ardizzoni A; Crinò L; Rindi G; Cascinu S
Lung Cancer; 2006 Jul; 53(1):103-9. PubMed ID: 16716446
[TBL] [Abstract][Full Text] [Related]
6. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer.
Strathdee G; MacKean MJ; Illand M; Brown R
Oncogene; 1999 Apr; 18(14):2335-41. PubMed ID: 10327053
[TBL] [Abstract][Full Text] [Related]
7. Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter.
Plumb JA; Strathdee G; Sludden J; Kaye SB; Brown R
Cancer Res; 2000 Nov; 60(21):6039-44. PubMed ID: 11085525
[TBL] [Abstract][Full Text] [Related]
8. Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma.
Geisler JP; Goodheart MJ; Sood AK; Holmes RJ; Hatterman-Zogg MA; Buller RE
Cancer; 2003 Nov; 98(10):2199-206. PubMed ID: 14601090
[TBL] [Abstract][Full Text] [Related]
9. Expression and promoter methylation status of mismatch repair gene hMLH1 and hMSH2 in epithelial ovarian cancer.
Zhang H; Zhang S; Cui J; Zhang A; Shen L; Yu H
Aust N Z J Obstet Gynaecol; 2008 Oct; 48(5):505-9. PubMed ID: 19032668
[TBL] [Abstract][Full Text] [Related]
10. Hsp27, Hsp70 and mismatch repair proteins hMLH1 and hMSH2 expression in peripheral blood lymphocytes from healthy subjects and cancer patients.
Nadin SB; Vargas-Roig LM; Drago G; Ibarra J; Ciocca DR
Cancer Lett; 2007 Jul; 252(1):131-46. PubMed ID: 17276589
[TBL] [Abstract][Full Text] [Related]
11. Loss of expression of DNA repair enzymes MGMT, hMLH1, and hMSH2 during tumor progression in gastric cancer.
Kitajima Y; Miyazaki K; Matsukura S; Tanaka M; Sekiguchi M
Gastric Cancer; 2003; 6(2):86-95. PubMed ID: 12861399
[TBL] [Abstract][Full Text] [Related]
12. The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients.
Gifford G; Paul J; Vasey PA; Kaye SB; Brown R
Clin Cancer Res; 2004 Jul; 10(13):4420-6. PubMed ID: 15240532
[TBL] [Abstract][Full Text] [Related]
13. Loss of DNA mismatch repair in acquired resistance to cisplatin.
Aebi S; Kurdi-Haidar B; Gordon R; Cenni B; Zheng H; Fink D; Christen RD; Boland CR; Koi M; Fishel R; Howell SB
Cancer Res; 1996 Jul; 56(13):3087-90. PubMed ID: 8674066
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical analysis of hMLH1 and hMSH2 proteins in serous ovarian tumours.
Stasikowska-Kanicka O; Stawerski P; Wagrowska-Danilewicz M; Danilewicz M
Pol J Pathol; 2009; 60(4):174-8. PubMed ID: 20072951
[TBL] [Abstract][Full Text] [Related]
15. Roles of mismatch repair proteins hMSH2 and hMLH1 in the development of sporadic breast cancer.
Murata H; Khattar NH; Gu L; Li GM
Cancer Lett; 2005 Jun; 223(1):143-50. PubMed ID: 15890247
[TBL] [Abstract][Full Text] [Related]
16. Influence of hMLH1 methylation, mismatch repair deficiency and microsatellite instability on chemoresistance of testicular germ-cell tumors.
Olasz J; Mándoky L; Géczi L; Bodrogi I; Csuka O; Bak M
Anticancer Res; 2005; 25(6B):4319-24. PubMed ID: 16309235
[TBL] [Abstract][Full Text] [Related]
17. Mutations of hMLH1 and hMSH2 in patients with suspected hereditary nonpolyposis colorectal cancer: correlation with microsatellite instability and abnormalities of mismatch repair protein expression.
Scartozzi M; Bianchi F; Rosati S; Galizia E; Antolini A; Loretelli C; Piga A; Bearzi I; Cellerino R; Porfiri E
J Clin Oncol; 2002 Mar; 20(5):1203-8. PubMed ID: 11870161
[TBL] [Abstract][Full Text] [Related]
18. BAT-26 microsatellite instability does not correlate with the loss of hMLH1 and hMSH2 protein expression in sporadic endometrial cancers.
Miturski R; Bogusiewicz M; Tarkowski R; Ciotta C; Bignami M; Burnouf D; Jakowicki JA
Oncol Rep; 2003; 10(4):1039-43. PubMed ID: 12792767
[TBL] [Abstract][Full Text] [Related]
19. Transient mismatch repair gene transfection for functional analysis of genetic hMLH1 and hMSH2 variants.
Brieger A; Trojan J; Raedle J; Plotz G; Zeuzem S
Gut; 2002 Nov; 51(5):677-84. PubMed ID: 12377806
[TBL] [Abstract][Full Text] [Related]
20. Microsatellite instability and hMLH1 and hMSH2 expression analysis in soft tissue sarcomas.
Kawaguchi K; Oda Y; Takahira T; Saito T; Yamamoto H; Kobayashi C; Tamiya S; Oda S; Iwamoto Y; Tsuneyoshi M
Oncol Rep; 2005 Feb; 13(2):241-6. PubMed ID: 15643505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
